Adjunctive celecoxib for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials

Wei Zheng, Dong Bin Cai, Xin Hu Yang, Gabor S. Ungvari, Chee H. Ng, Norbert Müller, Yu Ping Ning, Yu-Tao Xiang

    Research output: Contribution to journalArticle

    28 Citations (Scopus)

    Abstract

    Neuroinflammation has been implicated in the neurobiological pathways of schizophrenia. This meta-analysis evaluated the efficacy and tolerability of adjunctive celecoxib as a noncompetitive anti-inflammation drug in treating schizophrenia. Data were searched, extracted, checked and entered into the RevMan (version 5.3) software by two independent investigators. Standardized/weighted mean differences (SMDs/WMDs), risk ratio (RR) and their 95% confidence intervals (CIs) were calculated, as appropriate. Included were 8 randomized controlled trials (RCTs) with a total of 626 patients with schizophrenia including 316 (50.5%) treated on celecoxib (400 mg/day) and 310 (49.5%) on placebo over 8.3 ± 2.3 weeks of treatment. Adjunctive celecoxib outperformed placebo with respect to total psychopathology [3 RCTs, n = 180; SMD: −0.47; 95%CI: −0.81, −0.14; P = 0.005; I2 = 18%; 'moderate quality'], symptoms positive [3 RCTs, n = 180; SMD: −0.50; 95%CI: −0.79, −0.20; P = 0.001; I2 = 0%; 'moderate quality'], negative symptoms [3 RCTs, n = 180; SMD: −0.32; 95%CI: −0.66, 0.02; P = 0.06; I2 = 22%; 'moderate quality'], and general psychopathology scores [3 RCTs, n = 180; SMD: −0.35; 95%CI: −0.65, −0.06; P = 0.02; I2 = 0%; 'moderate quality'] in first-episode, but not chronic patients. Additionally, superiority of celecoxib for the Positive and Negative Syndrome Scale (PANSS) total scores was moderated by higher PANSS positive scores and lower PANSS negative scores at baseline. All-cause discontinuation [RR: 1.02; (95%CI: 0.56, 1.86); P = 0.94; I2 = 0%] and adverse drug reactions were similar between the two groups. Adjunctive celecoxib appears to be an efficacious and safe treatment in improving psychotic symptoms, particularly in first-episode schizophrenia. Review registration CRD42016054233 (http://www.crd.york.ac.uk/prospero/).

    Original languageEnglish
    Pages (from-to)139-146
    Number of pages8
    JournalJournal of Psychiatric Research
    Volume92
    DOIs
    Publication statusPublished - 1 Sep 2017

    Fingerprint Dive into the research topics of 'Adjunctive celecoxib for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials'. Together they form a unique fingerprint.

  • Cite this